| Literature DB >> 32977855 |
Xuemei Wang1, Yuqing Tang1, Chenxi Liu1, Junjie Liu2, Youwen Cui1, Xinping Zhang3.
Abstract
BACKGROUND: The overuse of antibiotics has been a major public health problem worldwide, especially in low- and middle- income countries (LMIC). However, there are few policies specific to antibiotic stewardship in primary care and their effectiveness are still unclear. A restrictive-prescribing stewardship targeting antibiotic use in primary care has been implemented since December 2014 in Hubei Province, China. This study aimed to evaluate the effects of the restrictive-prescribing stewardship on antibiotic consumption in primary care so as to provide evidence-based suggestions for prudent use of antibiotics.Entities:
Keywords: Antibiotic consumption; Interrupted time series analysis; Primary care; Quality indictors of European surveillance of antimicrobial consumption (ESAC QIs); Restrictive-prescribing stewardship
Year: 2020 PMID: 32977855 PMCID: PMC7519519 DOI: 10.1186/s13756-020-00821-7
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Quality indicators of measuring antibiotic consumption in this study
| NO. | Quality indicators |
|---|---|
| ESAC QIs 1–5 are the use of relevant antibiotics (expressed in DID): | |
| | |
| | |
| | |
| | |
| | |
| ESAC QIs 6–9 are the relative contributions (% of total J01 use) of: | |
| | |
| | |
| | |
| | |
| ESAC QI 10 is the ratio between broad- and narrow-spectrum antibiotics: | |
| | |
| QIs 11–14 are adapted according to the policy context in China (expressed in DID): | |
| | |
| | |
| | |
| | |
Fig. 1Monthly antibiotic consumption of systemic antibiotics, penicillins, quinolones, cephalosporins and macrolides/lincosamides/streptogramins
Fig. 2Monthly relative contributions of ß-lactamse-sentitive penicillins, combinations of penicillins with ß-lactamase inhibitors, third and fourth generation cephalosporins, fluoroquinolones to total use of systemic antibiotics
Fig. 3Monthly broad- and narrow-spectrum antibiotic consumption as well as the ratio between them
Fig. 4Monthly antibiotic consumption of oral and parenteral antibiotics
The segmented regression analysis of intervention on antibiotic consumption
| Baseline level (95% CI) | Baseline trend (95% CI) | Level change after intervention (95% CI) | Trend change after intervention (95% CI) | DW | |
|---|---|---|---|---|---|
| Systemic antibiotics | 10.7777*** (9.51, 12.05) | 0.0237 (− 0.06, 0.10) | − 2.4518** (− 4.14, − 0.76) | − 0.1193* (− 0.22, − 0.02) | 2.0572 |
| Penicillins | 4.8920*** (4.22, 5.56) | 0.0124 (− 0.03, 0.05) | − 1.9109*** (− 2.80, − 1.02) | −0.0553* (− 0.11, − 0.00) | 1.9703 |
| Cephalosporins | 3.1150*** (2.75, 3.48) | − 0.0015 (− 0.02, 0.02) | − 0.0262 (− 0.51,0.45) | −0.0294* (− 0.06, − 0.00) | 2.2194 |
| Macrolides/lincosamides/ streptogramins | 0.9053*** (0.75, 1.06) | 0.0099* (0.00, 0.02) | − 0.2248* (− 0.43, − 0.02) | − 0.0182** (− 0.03, − 0.01) | 1.9409 |
| Quinolones | 1.0594*** (0.93, 1.19) | −0.0005 (− 0.01, 0.01) | − 0.2019* (− 0.37, − 0.03) | − 0.0077 (− 0.02,0.00) | 2.0270 |
| ß-lactamse-sentitive penicillins | 7.2141*** (5.86, 8.57) | 0.0271 (− 0.06, 0.11) | − 2.9126** (− 4.55, − 1.27) | − 0.0825 (− 0.19, 0.03) | 2.0439 |
| Combinations of penicillins with ß-lactamase inhibitors | 2.6349*** (1.71, 3.56) | 0.0312 (−0.03, 0.09) | 1.2010 (− 0.01, 2.41) | 0.0618 (− 0.01, 0.13) | 1.9534 |
| Third and fourth generation cephalosporins | 16.2036*** (13.55, 18.85) | −0.1312 (− 0.30, 0.03) | 5.0352** (1.55, 8.52) | 0.1543 (− 0.05, 0.36) | 1.9815 |
| Fluoroquinolones | 9.7988*** (9.31, 10.29) | −0.0246 (− 0.05, 0.01) | 0.2156 (− 0.42, 0.85) | 0.0406* (0.00, 0.08) | 1.8880 |
| Broad | 3.6089*** (3.16, 4.06) | 0.0148 (−0.01, 0.04) | −0.1212 (− 0.72, 0.48) | −0.0423* (− 0.08, − 0.01) | 2.2142 |
| Narrow | 1.4481*** (1.24, 1.65) | 0.0055 (− 0.01, 0.02) | − 0.6449*** (− 0.92, − 0.37) | − 0.0223** (− 0.04, − 0.01) | 1.9398 |
| Broad /Narrow | 2.4977*** (1.65, 3.34) | 0.0032 (− 0.05, 0.06) | 1.8747** (0.78, 2.97) | 0.0500 (− 0.02, 0.12) | 1.9345 |
| Oral | 5.6076*** (4.73, 6.48) | 0.0221 (− 0.03, 0.08) | −1.9292** (−3.09, − 0.77) | −0.0815* (− 0.15, − 0.01) | 1.9424 |
| Parenteral | 5.1721*** (4.63, 5.71) | 0.0011 (− 0.03, 0.03) | −0.5049 (− 1.22, 0.21) | −0.0373 (− 0.08, 0.00) | 2.2052 |
Notes: *p < 0.05; **p < 0.01; ***p < 0.001;
CI Confidence intervals, DW Durbin-Watson